You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Singapore-based company will debut a system at AACC that performs real-time PCR flu A/B testing in less than 20 minutes for the cost of a lateral flow test.
The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.
The Dublin, Ireland-based company plans to launch its new instrument by the end of 2021 and will pursue CLIA waiver in the US.
The test uses unique PCR chemistries as well as a streamlined sample prep method to detect resistance mutations without DNA extraction.
The Frederick, Maryland-based firm has received regulatory clearance for a multiplexed array-based assay after more than 15 years in development.
The virology department at UW will offer a number of support services to diagnostics developers, including particular expertise in digital PCR and sequencing technologies.
The study showed that the Zeesan test kit and qPCR instrument could be used for near-patient HPV typing of 94 samples in 2.5 hours.
The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The upgrades include a method to connect Panther systems to create a higher-throughput system that can be configured to different footprints.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.